import os
from dotenv import load_dotenv

load_dotenv()

class Config:
    # API Keys
    TELEGRAM_TOKEN = os.getenv('TELEGRAM_TOKEN')
    TELEGRAM_CHAT_ID = os.getenv('TELEGRAM_CHAT_ID')
    GEMINI_API_KEY = os.getenv('GEMINI_API_KEY')
    FINNHUB_API_KEY = os.getenv('FINNHUB_API_KEY')  # ì„ íƒì‚¬í•­ (í˜„ì¬ ì‚¬ìš© ì•ˆ í•¨)
    ALPHA_VANTAGE_KEY = os.getenv('ALPHA_VANTAGE_KEY')  # ì„ íƒì‚¬í•­ (í˜„ì¬ ì‚¬ìš© ì•ˆ í•¨)
    DART_API_KEY = os.getenv('DART_API_KEY')
    
    @classmethod
    def validate(cls):
        # í•„ìˆ˜ API í‚¤ë§Œ ê²€ì¦ (Finnhub, Alpha VantageëŠ” í˜„ì¬ ì‚¬ìš© ì•ˆ í•¨)
        required = ['TELEGRAM_TOKEN', 'TELEGRAM_CHAT_ID', 'GEMINI_API_KEY']
        missing = [k for k in required if not getattr(cls, k)]
        if missing: raise ValueError(f"ëˆ„ë½ëœ API í‚¤: {missing}")
    
    # í•„í„° ì„¤ì •
    MIN_MARKET_CAP = 10_000_000
    MAX_MARKET_CAP = 100_000_000_000_000
    
    MIN_PRICE = 0.3
    MAX_PRICE = 5000.0
    
    MIN_VOLUME_INCREASE = 200
    MIN_PRICE_CHANGE = 10.0
    MIN_AI_SCORE = 7
    
    # 200% ê¸‰ë“± í‚¤ì›Œë“œ (í¼í”Œë ‰ì‹œí‹° ë°ì´í„° ê¸°ë°˜ + QNCX/EVMN ê°•í™”)
    POSITIVE_KEYWORDS = [
        # === 1. FDA/ë°”ì´ì˜¤ (35% - ê°€ì¥ ê°•ë ¥) ===
        'fda approval', 'fda approved', 'fda clearance', 'fda grants',
        'regulatory approval', 'marketing authorization', 'ce mark',
        'surprise fda nod', 'unexpected approval',
        
        # ì„ìƒ ì„±ê³µ
        'clinical trial', 'phase 3', 'phase 2', 'phase 1',
        'primary endpoint met', 'statistically significant', 'superior efficacy',
        'positive data', 'positive results', 'met primary endpoint',
        'trial success', 'successful trial', 'pivotal trial',
        
        # ğŸ†• Top-line ë°ì´í„° (EVMN 45% ì¼€ì´ìŠ¤!)
        'positive top-line', 'positive topline',
        'positive top-line data', 'positive topline data',
        'top-line data', 'topline results',
        'announces positive top-line',
        
        # ğŸ†• POC (Proof of Concept) - EVMN!
        'proof-of-concept', 'proof of concept', 'poc trial',
        'poc study', 'concept study', 'proof-of-concept trial',
        'phase 2a proof-of-concept',
        
        # ğŸ†• Primary Endpoint ê°•í™”
        'met its primary endpoint', 'achieved primary endpoint',
        'primary endpoint achieved',
        
        # ğŸ†• ì„ìƒ ê²°ê³¼ ì§€í‘œ
        'durable response', 'sustained response',
        'complete response', 'partial response',
        'objective response rate', 'orr',
        'progression-free survival', 'pfs',
        'overall survival', 'os improvement',
        'disease control rate',
        
        # í¬ê·€ì§ˆí™˜/íŠ¹ìˆ˜ ì§€ìœ„
        'orphan drug', 'breakthrough therapy', 'fast track',
        'priority review', 'accelerated approval',
        'rare disease', 'first-in-class', 'best-in-class',
        
        # í™•ëŒ€ í”„ë¡œê·¸ë¨
        'expanded access', 'compassionate use',
        'emergency use authorization', 'eua',
        
        # ë¼ì´ì„¼ì‹±
        'licensing agreement', 'license deal', 'global rights',
        'exclusive license', 'milestone payment',
        
        # ğŸ†• ì¶”ê°€ ë°”ì´ì˜¤ ì´ë²¤íŠ¸
        'investigational new drug', 'ind clearance', 'ind application',
        'rolling submission', 'rolling review',
        'complete response letter lifted', 'crl lifted',
        'advisory committee', 'adcom positive',
        'label expansion', 'indication expansion',
        
        # ğŸ†• ì ì‘ì¦ ì¤‘ìš”ë„ (EVMN!)
        'moderate-to-severe', 'moderate to severe',
        'severe', 'refractory', 'resistant',
        'advanced stage', 'metastatic', 'late-stage', 'late stage',
        
        # ğŸ†• ì§ˆí™˜ ì¢…ë¥˜ (ì‹œì¥ í¬ê¸°)
        'atopic dermatitis', 'psoriasis', 'eczema',
        'cancer', 'oncology', 'tumor',
        'alzheimer', 'parkinson',
        
        # === 2. M&A (25% - ì¦‰ê° ê¸‰ë“±) ===
        'merger', 'acquisition', 'buyout', 'takeover',
        'tender offer', 'all-cash offer',
        'acquired by', 'to be acquired', 'agrees to acquire',
        'definitive agreement', 'merger agreement',
        'strategic alternatives', 'exploring strategic options',
        'going private', 'take private',
        
        # ğŸ†• M&A ê°•í™” (QNCX 120% ì¼€ì´ìŠ¤!)
        'exploring strategic alternatives', 'explore strategic alternatives',
        'strategic alternative', 'reviewing strategic alternatives',
        'strategic review', 'strategic process',
        'sale process', 'exploring sale', 'potential sale', 'explore sale',
        'financial advisor', 'exclusive financial advisor',
        'engaged as financial advisor', 'engaged as exclusive',
        'lifesci capital', 'investment bank',
        
        # === 3. ì •ë¶€/êµ­ê°€ ì „ëµ (20%) ===
        'government contract', 'doj contract', 'defense contract',
        'awarded contract', 'contract win', 'contract award',
        'government stake', 'sovereign investment',
        'national security', 'critical minerals', 'strategic resource',
        'subsidy', 'grant awarded', 'government funding',
        
        # === 4. IPO/SPAC (15%) ===
        'ipo', 'initial public offering', 'debut',
        'spac merger', 'business combination', 'merger completion',
        'de-spac', 'nasdaq debut', 'nyse debut',
        'oversubscribed', 'upsized offering',
        
        # === 5. íŒŒíŠ¸ë„ˆì‹­/ì „ëµì  ì œíœ´ ===
        'partnership', 'strategic partnership', 'collaboration',
        'nvidia partnership', 'nvidia isaac',
        'joint venture', 'co-development',
        'supply agreement', 'supply deal', 'offtake agreement',
        
        # ğŸ†• ëŒ€í˜• íŒŒíŠ¸ë„ˆ (ì‹ ë¢°ë„)
        'pfizer partnership', 'roche collaboration',
        'novartis agreement', 'merck deal',
        'jnj partnership', 'bristol myers',
        
        # ğŸ†• ê³„ì•½ ê°•í™”
        'opt-in rights', 'option agreement',
        'co-commercialization', 'royalty agreement', 'profit sharing',
        
        # === 6. ì‹¤ì  ì„œí”„ë¼ì´ì¦ˆ (5%) ===
        'earnings beat', 'revenue beat', 'guidance raised',
        'record revenue', 'record earnings', 'record sales',
        'blowout quarter', 'massive beat',
        'upgraded guidance', 'raised outlook',
        
        # === 7. ë¬´ì—­/ì •ì±… ===
        'tariff', 'trade policy', 'import ban',
        'china ban', 'alternative supplier', 'supply chain shift',
        
        # === 8. ì•”í˜¸í™”í/ë¸”ë¡ì²´ì¸ ===
        'ethereum treasury', 'bitcoin treasury', 'crypto strategy',
        'vitalik buterin', 'board chairman', 'eth holdings',
        
        # === 9. í•œêµ­ í‚¤ì›Œë“œ ===
        'ìŠ¹ì¸', 'í—ˆê°€', 'ê³„ì•½', 'ìˆ˜ì£¼', 'íŠ¹í—ˆ',
        'ì„ìƒ', 'ì„±ê³µ', 'í•©ë³‘', 'ì¸ìˆ˜', 'M&A',
        'ì •ë¶€ ê³„ì•½', 'êµ­ë°©', 'ë°©ì‚°', 'ìˆ˜ì¶œ',
        'í‘ìì „í™˜', 'ì‹¤ì ', 'ì‹ ì•½', 'ì œíœ´'
    ]
    
    NEGATIVE_KEYWORDS = [
        # === 1. ìê¸ˆ ì¡°ë‹¬ (í¬ì„) ===
        'offering', 'direct offering', 'public offering',
        'registered direct offering', 'shelf offering',
        'secondary offering', 'follow-on offering',
        'at-the-market offering', 'atm offering',
        'dilution', 'dilutive', 'share issuance',
        'stock issuance', 'warrant exercise',
        
        # ğŸ†• ìê¸ˆ ì¡°ë‹¬ ê°•í™”
        'rights offering', 'pipe offering',
        
        # === 2. ê¸°ì—… ì¡´ì† ìœ„í—˜ ===
        'bankruptcy', 'chapter 11', 'chapter 7',
        'delisting', 'nasdaq delisting', 'deficiency notice',
        'going concern', 'substantial doubt',
        'wind down', 'liquidation',
        
        # === 3. ë²•ì /ê·œì œ ë¦¬ìŠ¤í¬ ===
        'investigation', 'sec investigation', 'doj investigation',
        'lawsuit', 'class action', 'securities fraud',
        'subpoena', 'criminal charges',
        'recall', 'product recall', 'safety recall',
        'warning letter', 'fda warning', 'crl',
        'rejected', 'denial', 'failed to meet',
        
        # ğŸ†• ê·œì œ ê°•í™”
        'complete response letter', 'clinical hold',
        
        # === 4. ì£¼ì‹ êµ¬ì¡° ì•…ì¬ ===
        'reverse split', 'reverse stock split',
        'stock split', 'share consolidation',
        
        # === 5. ê±°ë˜ ì¤‘ë‹¨ ===
        'suspended', 'trading halt', 'halted',
        'circuit breaker', 'volatility halt',
        
        # === 6. ì˜ê²¬/ì „ë§ (ë…¸ì´ì¦ˆ) - ğŸ†• ëŒ€í­ ê°•í™” ===
        'analyst says', 'analyst ratings', 'analyst opinion',
        'price target', 'upgraded', 'downgraded',
        'opinion', 'preview', 'outlook', 'forecast',
        'summary', 'recap', 'market wrap',
        'why it moved', 'what to watch', 'what happened',
        
        # ğŸ†• ë…¸ì´ì¦ˆ ëŒ€í­ ê°•í™”
        'stock movers', 'pre-market', 'after-hours',
        'morning brief', 'market watch', 'stock alert',
        'penny stock', 'meme stock',
        'stock to watch', 'stocks to buy',
        'sponsored', 'advertisement', 'paid promotion',
        'investor presentation', 'roadshow',
        'quarterly update', 'monthly update',
        'business update', 'corporate update',
        'conference call', 'webcast',
        'to host', 'will host', 'to present', 'will present',
        'files 10-k', 'files 10-q',
        'annual report', 'quarterly report',
        
        # === 7. ê³µë§¤ë„ ===
        'short seller', 'short report', 'short interest',
        'hindenburg', 'citron', 'muddy waters',
        
        # === 8. í•œêµ­ ì•…ì¬ ===
        'ë£¨ë¨¸', 'ì¶”ì •', 'ì „ë§', 'ì˜ˆìƒ',
        'ì ì', 'ì†Œì†¡', 'ìœ ìƒì¦ì', 'ê°ì',
        'ê±°ë˜ì •ì§€', 'ìƒì¥íì§€', 'ë¶„ì‹íšŒê³„'
    ]

    REDDIT_MIN_MENTIONS = 10
    REDDIT_SUBREDDITS = ['wallstreetbets', 'stocks', 'investing', 'pennystocks']

try:
    Config.validate()
except ValueError as e:
    print(f"âš ï¸ ì„¤ì • ì˜¤ë¥˜: {e}")